Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
about
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer CenterSkin cancer in organ transplant recipients: more than the immune system.Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.Rates of Cancers and Opportunistic Infections in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis.Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis.Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT RegistrySafety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Increased Incidence of Critical Illness in Psoriasis.Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.Is there any link between tumor-induced osteomalacia and psoriasis? A case report.Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Epidermal PPARγ influences subcutaneous tumor growth and acts through TNF-α to regulate contact hypersensitivity and the acute photoresponse.Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
P2860
Q27314686-8076A8C0-91BC-4A53-8DBF-4F9836832B17Q33923227-F5FC50DD-D75E-42E5-B3FD-5DD601C3FA14Q35606402-D8910FB9-97C8-4E80-935F-19AE51B49755Q36316271-67F56D9D-B137-4A37-84EC-468C9500A864Q37139101-4F63CF47-4EB3-48F0-8E94-AB5A4D772149Q37630268-561B0BD2-DC98-4DBF-9B88-908725E9EB3CQ38225574-DDB6485F-64E2-4B90-A000-A93190F34095Q38372071-FCDF0C10-04A4-4A22-BB32-7B111B7081D8Q38611360-7E6D4CB6-B549-4ACB-9281-CBBA83E5CB6BQ38740215-CE5CF2E8-8567-42D6-9695-AD0D28C3CE94Q41057850-938C3C31-8F17-4310-8EA8-B2042CB57F61Q41491518-58B5335E-2AA6-407F-BA7A-D86C3940865EQ45977850-C86A9E4D-B3E2-4132-88E4-149119F50DD4Q47139765-F179FAD6-39B5-4F6B-974A-37406100DCD1Q48089393-FB8F4475-C361-4839-9B91-3ED89AB788CC
P2860
Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Incidence rates of malignancie ...... lation in the U.S.A.: 2005-09.
@en
Incidence rates of malignancie ...... lation in the U.S.A.: 2005-09.
@nl
type
label
Incidence rates of malignancie ...... lation in the U.S.A.: 2005-09.
@en
Incidence rates of malignancie ...... lation in the U.S.A.: 2005-09.
@nl
prefLabel
Incidence rates of malignancie ...... lation in the U.S.A.: 2005-09.
@en
Incidence rates of malignancie ...... lation in the U.S.A.: 2005-09.
@nl
P2093
P2860
P356
P1476
Incidence rates of malignancie ...... ulation in the U.S.A.: 2005-09
@en
P2093
J Schenfeld
K J Rothman
M S Anthony
N A Accortt
P2860
P304
P356
10.1111/BJD.12744
P407
P577
2014-02-01T00:00:00Z